ABBV Dividend Calculator
Dividend growth rate (CAGR)
| Year | Yield | Div / share | Annual income | Yield on cost | Cumulative income | Portfolio value | Shares |
|---|---|---|---|---|---|---|---|
| 1 | 2.8% | $6.74 | $320.00 | 2.6% | $320.00 | $14,134 | 59.59 |
| 2 | 2.7% | $7.15 | $425.94 | 2.9% | $745.94 | $18,900 | 70.80 |
| 3 | 2.5% | $7.58 | $536.34 | 3.1% | $1,282 | $24,379 | 81.15 |
| 4 | 2.4% | $8.03 | $651.51 | 3.3% | $1,934 | $30,668 | 90.71 |
| 5 | 2.2% | $8.51 | $771.80 | 3.5% | $2,706 | $37,873 | 99.54 |
| 6 | 2.1% | $9.02 | $897.55 | 3.7% | $3,603 | $46,114 | 107.69 |
| 7 | 2.0% | $9.56 | $1,029 | 3.8% | $4,632 | $55,528 | 115.23 |
| 8 | 1.9% | $10.13 | $1,167 | 4.0% | $5,799 | $66,269 | 122.19 |
| 9 | 1.8% | $10.73 | $1,312 | 4.2% | $7,111 | $78,510 | 128.63 |
| 10 | 1.7% | $11.38 | $1,463 | 4.3% | $8,574 | $92,446 | 134.59 |
Year 1-10 dividend income (preview)
Based on a $10,000 initial investment with $200.00 monthly contributions, DRIP on.
Historical dividends per share
Recent dividends
| Ex-date | Cash amount | TTM yield | Fwd yield | Share price |
|---|---|---|---|---|
| 2026-04-15 | $1.73 | 3.2% | 3.3% | $208.42 |
| 2026-01-16 | $1.73 | 3.1% | 3.2% | $214.35 |
| 2025-10-15 | $1.64 | 2.9% | 2.9% | $226.22 |
| 2025-07-15 | $1.64 | 3.5% | 3.5% | $186.39 |
| 2025-04-15 | $1.64 | 3.6% | 3.7% | $176.80 |
| 2025-01-15 | $1.64 | 3.7% | 3.8% | $171.35 |
| 2024-10-15 | $1.55 | 3.2% | 3.2% | $191.86 |
| 2024-07-15 | $1.55 | 3.6% | 3.7% | $168.03 |
| 2024-04-12 | $1.55 | 3.7% | 3.8% | $162.28 |
| 2024-01-12 | $1.55 | 3.7% | 3.8% | $162.40 |
| 2023-10-12 | $1.48 | 4.9% | 4.0% | $148.30 |
| 2023-07-13 | $1.48 | 5.4% | 4.4% | $133.59 |
Source: Polygon.io. Last 12 dividend distributions, most recent first. TTM yield = sum of last 12 months of payments ÷ share price on ex-date. Forward yield = this payment × detected payout frequency ÷ share price on ex-date.
About ABBV
AbbVie Inc. — ticker ABBV — is a large-cap US pharmaceutical company that emerged as an independent business in January 2013, when Abbott Laboratories split its research-based pharmaceutical division off as a separate publicly traded company. The dividend story carries a specific piece of inherited lineage that's worth explaining carefully upfront, because it shapes how AbbVie is commonly classified and what claims about its streak are appropriate. At the time of the 2013 spinoff, Abbott Laboratories had a consecutive-annual-increase streak of more than forty years. The spinoff was structured such that the streak number remained with Abbott — ABT continued counting forward from its existing total — but AbbVie has also been raising its dividend every year since the 2013 separation, an unbroken record across its full life as an independent company. Because AbbVie inherited the dividend mandate, capital-allocation discipline, and shareholder base of the pre-2013 Abbott parent, AbbVie's official communications and most third-party dividend-tracker services credit the company with the full pre-spinoff streak — currently fifty-two years or more on a combined basis. The honest framing for an income investor is: AbbVie has approximately twelve years of independent dividend-increase history plus inheritance of the pre-2013 Abbott streak, which together produce the fifty-plus-year track record commonly cited. Both Abbott and AbbVie credit themselves with that lineage; double-counting the same streak years when comparing the two should be avoided.
AbbVie operates in the Healthcare sector, specifically branded pharmaceuticals. The company's historical center of gravity was Humira, an immunology drug for rheumatoid arthritis and related autoimmune conditions that became the best-selling pharmaceutical product in the world for most of the 2010s. Humira's US patent protection ended in 2023, opening the US market to biosimilar competition. AbbVie's response — anticipated and planned for years in advance — has been a portfolio transition centered on the immunology successors Skyrizi and Rinvoq, both of which have been ramping revenue rapidly to offset the Humira erosion. The portfolio also includes aesthetics products (Botox, Juvederm) acquired through the 2020 Allergan deal, oncology drugs (Imbruvica, Venclexta), and neuroscience treatments. The Humira-cliff transition is real and ongoing, and modeling AbbVie's dividend coverage requires looking at the combined post-Humira portfolio rather than legacy-Humira figures.
The dividend mandate has been treated as a structural commitment since the 2013 spinoff, consistent with the inherited Abbott capital-allocation tradition. Management has continued annual increases through the Humira-cliff window, including across 2023 and 2024 when Humira revenue erosion was at its most material, supported by the Skyrizi-and-Rinvoq ramp and by the broader portfolio's free cash flow. Expense ratio is not applicable to individual stocks — the figure you'll see in the calculator above is zero, since there is no fund wrapper between you and the underlying shares. The dividend has not been cut in AbbVie's independent history, and the inherited pre-2013 Abbott streak was never cut in modern history either, which is the relevant test for a Dividend King.
How ABBV pays dividends
AbbVie pays cash dividends quarterly, on a February–May–August–November cadence. The board declares the per-share amount each quarter; the ex-dividend date typically falls in the third or fourth week of the first month of the cycle, and the pay date falls roughly two weeks after the ex-date. Holders who own shares as of the close on the day before the ex-date receive the dividend; holders who buy on or after the ex-date wait for the next quarterly payment. On the ex-date the share price drops by approximately the distribution amount on the open, reflecting the fact that the company has paid the cash out of its balance sheet.
Holders who DRIP through their broker receive additional shares purchased at the prevailing market price around the pay date. Most major brokers offer fractional-share DRIP for AbbVie, so the full cash distribution is reinvested even when the per-share amount divided by the share price doesn't produce a whole number. The mechanics are identical to any other quarterly US dividend stock — there is no managed-distribution policy, no covered-call overlay, and the cash that funds the dividend comes from operating free cash flow generated by the immunology, aesthetics, oncology, and neuroscience portfolios combined.
Recent growth pattern: AbbVie has typically raised the quarterly per-share amount once per year, with the new rate taking effect on the dividend payment following the autumn announcement. The size of the annual hike has historically run in the mid-to-high single digits — higher than most mature Dividend Kings, reflecting AbbVie's relatively shorter standalone history and stronger underlying revenue growth before the Humira cliff. Growth has moderated somewhat during the Humira-transition window as management balances dividend continuity against debt-reduction priorities tied to the 2020 Allergan acquisition. The calculator on this page uses a recent dividend growth rate to project the income line forward; given the post-Humira-cliff portfolio transition, modeling AbbVie with a slightly more conservative growth assumption than the pre-2023 trailing average is generally more honest.
AbbVie's dividends are qualified for the long-term capital-gains rate in taxable accounts, given the standard sixty-day holding-period rule. Most buy-and-hold investors clear this threshold easily. In tax-advantaged accounts the qualified-dividend treatment is moot because no current-year tax applies.
Who ABBV suits
AbbVie suits investors who want pharmaceutical-sector exposure with a high current yield relative to most Dividend Kings — typically in the three-to-four-percent range, sometimes higher — and who are comfortable with the underlying Humira-cliff transition risk. The yield sits well above the broader S&P 500 average and reflects both the maturity of the pharma business model and the market's pricing of patent-cliff uncertainty in the immunology franchise. The trade-off is the canonical pharma-with-patent-exposure pattern: higher current yield in exchange for the work of evaluating whether the successor portfolio (Skyrizi, Rinvoq, aesthetics, oncology, neuroscience) can sustain the cash flow that supported the dividend during the Humira-revenue peak. Recent results suggest the transition is tracking, but the multi-year arc remains an open variable.
The comparison readers most often want is ABBV versus ABT — the lineage twin. AbbVie was spun off from Abbott in January 2013, and the two companies share a corporate history through that point. After the spinoff, Abbott kept the streak number — its current Dividend King status of fifty-plus years is the continuation of the pre-2013 record — while AbbVie inherited the dividend mandate and the underlying shareholder base. AbbVie credits itself with the same pre-2013 lineage in its King classification on a combined basis. The substantive comparison is not about the streak number but about the underlying businesses: ABT operates in medical devices, diagnostics, nutrition, and branded generics — a diversified healthcare conglomerate with lower yield and slower per-share dividend growth — while ABBV operates in branded pharmaceuticals with higher yield, faster per-share growth, and more concentrated patent-cliff exposure. Holding both gives diversified pre-2013-Abbott-lineage exposure across the two sides of the original company.
In taxable accounts, AbbVie's dividends are qualified for the long-term capital-gains rate. In tax-advantaged accounts the treatment is moot. As with any single-stock position, this content is educational only; it is not a recommendation to buy, sell, or hold AbbVie, and individual circumstances vary. Pharmaceutical-sector-specific risks — including ongoing biosimilar competition for Humira, the trajectory of the Skyrizi-and-Rinvoq franchise, and broader US drug-pricing policy — should be weighed against the dividend continuity record.
Hypothetical scenarios
Scenario 1: $10,000 invested in AbbVie at the January 2013 spinoff
Consider a hypothetical purchase of $10,000 of AbbVie stock at the start of January 2013, immediately after the spinoff from Abbott Laboratories that created the company in its current corporate shape. We use this entry point deliberately, because it corresponds to AbbVie's full independent history rather than blending it with the pre-spinoff Abbott record. At that point AbbVie had just inherited the immunology franchise centered on Humira, the dividend was set at the post-spinoff per-share rate, and the company was beginning its life as a standalone publicly traded pharma. The January 2013 entry price implied a per-share figure in the low-to-mid thirties, and the initial $10,000 would have purchased roughly three hundred shares.
Holding from 2013 through to the present, with quarterly dividends reinvested via DRIP, three forces compound together. First, the per-share dividend grew each year as AbbVie continued the annual-increase pattern inherited from the pre-2013 Abbott tradition — over its independent history, the per-share figure has increased several times over, with mid-to-high single-digit annual growth before the Humira cliff and somewhat moderated growth through the cliff window. Second, the share count grew as DRIP reinvested every quarterly distribution at the prevailing market price; given AbbVie's relatively high entry yield, share-count growth alone, independent of price, would have meaningfully increased the income line by the end of the period. Third, the share price climbed broadly across the holding window, supported by Humira's peak years before 2023 and by the Skyrizi-and-Rinvoq ramp through the cliff transition, with sector-specific drawdowns at various points.
The illustrative outcome is not a precise dollar figure. It depends on the exact reinvestment prices, dividend taxes paid along the way in a taxable account, and the specific entry and exit timing. The structural point is that AbbVie's combined per-share dividend growth, share-count growth from DRIP at a high entry yield, and long-run price growth compounded against the same initial position for the full independent history of the company — and that the dividend has been maintained and grown through the most material business transition in the company's life: the loss of US Humira exclusivity in 2023. ABBV is offered as a structural illustration, not a forecast.
Scenario 2: $50,000 today plus $500/month for 20 years
Consider a hypothetical accumulation strategy in AbbVie: $50,000 starting capital, plus $500 per month added on a regular cadence for 20 years. The calculator on this page can model this exactly — set Initial investment to $50,000, Extra contribution to $500, Contribution frequency to Monthly, time horizon to 20 years, and leave DRIP on.
The mechanics: each month, the new $500 buys additional shares at the current price, which adds to the share count and therefore to next quarter's dividend. Each quarter, the dividend received from all accumulated shares is reinvested, adding more shares at the prevailing price. Because AbbVie's entry yield is higher than the broader-market average — typically in the three-to-four-percent range, sometimes higher — the DRIP component contributes a relatively larger share of share-count growth than the same DCA setup would for a lower-yield dividend grower. Over 20 years this dual-track accumulation — DCA contributions plus dividend reinvestment — produces a position whose annual cash distribution is substantial, even before considering any potential price appreciation.
What's worth focusing on is the annual dividend column in the projection table. The first few years are slow because the base of dividend-generating shares is small; by year ten the annual dividend has grown significantly above year one; by year twenty the income line has compounded substantially. The dividend-growth-rate assumption is the most sensitive lever — modeling AbbVie with a more conservative growth assumption than its pre-2023 historical average is the structurally honest approach during the Humira-cliff transition. Real outcomes depend on AbbVie's future capital allocation, the trajectory of the Skyrizi-and-Rinvoq franchise relative to the Humira erosion, US drug-pricing policy, tax treatment, and the broader path of US equity markets. Educational only; not a forecast.
Sources & methodology
Dividend history and price data come from Polygon.io's reference and aggregates endpoints. Forward yield is computed as the sum of the most recent four cash distributions divided by the previous-close share price. The dividend growth rate shown on this page is the compound annual growth rate of total annual distributions across the available history in this snapshot.
Last updated: 2026-05-15.
Information here is for educational purposes only and does not constitute investment advice. Past dividend history does not guarantee future payments. Verify all figures with the issuer or a registered financial advisor before making investment decisions.